文献速递精神分裂症与精神病性障碍

精神病性障碍的神经影像异质性:神经生物学基础及预后与治疗创新的机遇

Neuroimaging Heterogeneity in Psychosis: Neurobiological Underpinnings and Opportunities for Prognostic and Therapeutic Innovation.
PubMed 文献 · Biol Psychiatry · 2019-09-17

本文指出精神分裂症或精神病性障碍在症状、结局和治疗反应上高度异质,可能不存在单一通用疾病标记,而应利用这种异质性识别神经生物学通路以用于患者分层。领域需转向大样本、统计效力充足的研究,并借助计算方法推动数据驱动策略,但新亚组的纵向稳定性、效度和可重复性仍是挑战。

要点

  • 精神病性障碍可能不存在单一通用生物标记,应视为共享与独特神经生物学通路并存的一组疾病。
  • 利用异质性进行患者分层,有望服务于预后判断或治疗试验。
  • 数据驱动方法识别的新亚组需验证纵向稳定性、效度和可重复性,并以预后准确性和治疗反应改善为检验标准。

核心结论

  • 精神病性障碍的症状、结局和治疗反应异质性长期妨碍通用生物标记的识别,可能根本不存在此类标记。
  • 利用或放大异质性的策略有助于发现可用于预后分层或治疗试验的神经生物学通路。

研究设计与样本

  • 本文为综述性论述,未报告原始研究设计或样本量。

主要发现

  • 同一临床诊断的个体在脑、遗传和行为层面可能比不同障碍或非临床对照个体差异更大。
  • 领域优先事项转向大样本和充足统计效力,以克服小效应量并区分脑影像或行为变量间的共享方差。
  • 计算进展推动数据驱动方法发展,但新亚组的纵向稳定性、效度证明和可重复性构成新兴挑战。

关键数值与推荐

  • 关键检验标准是计算方法识别的患者组是否比当前DSM诊断构建提供更好的纵向预后准确性并改善治疗反应和结局。
  • 原文未报告具体数值、比例、阈值、剂量、样本量或P值。

临床怎么用

  • 临床可关注基于神经生物学通路的患者分层思路,而非依赖单一通用生物标记。
  • 对数据驱动识别的新亚组应保持审慎,需等待纵向稳定性、效度和可重复性验证。
  • 预后准确性和治疗反应改善是评估新分层方法临床价值的核心指标。

局限性

  • 新亚组的纵向稳定性尚未确立。
  • 新亚组的效度和可重复性仍需证明。
  • 计算方法的临床价值需以预后准确性和治疗反应改善为检验标准,尚待验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heterogeneity in symptom presentation, outcomes, and treatment response has long been problematic for researchers aiming to identify biological markers of schizophrenia or psychosis. However, there is increasing recognition that there may likely be no such general illness markers, which is consistent with the notion of a group of schizophrenia(s) that may have both shared and unique neurobiological pathways. Instead, strategies aiming to capitalize on or leverage such heterogeneity may help uncover neurobiological pathways that may then be used to stratify groups of patients for prognostic purposes or for therapeutic trials. A shift toward larger sample sizes with adequate statistical power to overcome small effect sizes and disentangle the shared variance among different brain-imaging or behavioral variables has become a priority for the field. In addition, recognition that two individuals with the same clinical diagnosis may be more different from each other (at brain, genetic, and behavioral levels) than from another individual in a different disorder or nonclinical control group-coupled with computational advances-has catapulted data-driven efforts forward. Emerging challenges for this new approach include longitudinal stability of new subgroups, demonstration of validity, and replicability. The "litmus test" will be whether computational approaches that are successfully identifying groups of patients who share features in common, more than current DSM diagnostic constructs, also provide better prognostic accuracy over time and in addition lead to enhancements in treatment response and outcomes. These are the factors that matter most to patients, families, providers, and payers.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Voineskos AN, Jacobs GR, Ameis SH, et al. Neuroimaging Heterogeneity in Psychosis: Neurobiological Underpinnings and Opportunities for Prognostic and Therapeutic Innovation. Biol Psychiatry. 2019. PMID: 31668548. doi:10.1016/j.biopsych.2019.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。